文献速递胃肠动力与功能性疾病

肠易激综合征患者小肠细菌过度生长:病例对照研究的系统评价与Meta分析

Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该系统评价与Meta分析纳入25项病例对照研究(3192例IBS患者、3320例对照),比较小肠细菌过度生长(SIBO)患病率。IBS患者SIBO总体OR为3.7(95%CI 2.3-6.0),仅用健康对照时OR为4.9(95%CI 2.8-8.6)。不同诊断方法下患病率差异显著;IBS腹泻型较便秘型SIBO的OR为1.86(95%CI 1.83-2.8),甲烷阳性呼气试验在便秘型更常见。

要点

  • IBS患者SIBO患病率显著高于对照,总体OR=3.7(95%CI 2.3-6.0)。
  • 仅用健康对照的研究中,IBS患者SIBO的OR升至4.9(95%CI 2.8-8.6)。
  • IBS腹泻型较便秘型SIBO的OR为1.86(95%CI 1.83-2.8), methane阳性更见于便秘型。

核心结论

  • 该系统评价与Meta分析提示IBS与SIBO存在关联,但整体证据质量低。

主要发现

  • IBS患者SIBO患病率较对照显著升高,OR=3.7(95%CI 2.3-6.0)。
  • 仅纳入健康对照的研究中,IBS患者SIBO的OR=4.9(95%CI 2.8-8.6)。
  • 呼气试验诊断的SIBO患病率在IBS患者为35.5%(95%CI 33.6-37.4),对照为29.7%(95%CI 27.6-31.8)。
  • 培养法( cutoff 10 CFU/mL)SIBO患病率在IBS患者为13.9%(95%CI 11.5-16.4),对照为5.0%(95%CI 3.9-6.2);另一 cutoff(原文表述为10 colony-forming unit per milliliter)下IBS患者为33.5%(95%CI 30.1-36.9),对照为8.2%(95%CI 6.8-9.6)。
  • 乳果糖呼气试验诊断的SIBO患病率较葡萄糖呼气试验在IBS患者高3.6倍、对照高7.6倍;IBS腹泻型较便秘型SIBO的OR=1.86(95%CI 1.83-2.8),甲烷阳性呼气试验在便秘型更常见(OR=2.3,95%CI 1.2-4.2);IBS患者中质子泵抑制剂与SIBO无关(OR=0.8,95%CI 0.5-1.5,P=0.55)。

临床怎么用

  • 对IBS患者考虑SIBO诊断时,应知晓不同呼气试验和培养法患病率差异大,结果解读需结合方法学。

局限性

  • 整体证据质量低,主要因病例与对照选择标准不统一导致显著临床异质性。
  • 现有诊断试验的敏感性和特异性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We conducted a systematic review and meta-analysis to compare the prevalence of small intestinal bacterial overgrowth (SIBO) in patients with irritable bowel syndrome (IBS) and controls. METHODS: Electronic databases were searched up to December 2018 for studies reporting SIBO prevalence in patients with IBS. Prevalence rates, odds ratios (ORs), and 95% confidence intervals (CIs) of SIBO in patients with IBS and controls were calculated. RESULTS: We included 25 studies with 3,192 patients with IBS and 3,320 controls. SIBO prevalence in patients with IBS was significantly increased compared with controls (OR = 3.7, 95% CI 2.3-6.0). In studies using only healthy controls, the OR for SIBO in patients with IBS was 4.9 (95% CI 2.8-8.6). With breath testing, SIBO prevalence in patients with IBS was 35.5% (95% CI 33.6-37.4) vs 29.7% (95% CI 27.6-31.8) in controls. Culture-based studies yielded a SIBO prevalence of 13.9% (95% CI 11.5-16.4) in patients with IBS and 5.0% (95% CI 3.9-6.2) in controls with a cutoff value of 10 colony-forming units per milliliter vs 33.5% (95% CI 30.1-36.9) in patients with IBS and 8.2% (95% CI 6.8-9.6) in controls with a cutoff value of 10 colony-forming unit per milliliter, respectively. SIBO prevalence diagnosed by lactulose breath test is much greater in both patients with IBS (3.6-fold) and controls (7.6-fold) compared with glucose breath test. Similar difference is seen when lactulose breath test is compared with culture methods. OR for SIBO in patients with IBS-diarrhea compared with IBS-constipation was 1.86 (95% CI 1.83-2.8). Methane-positive breath tests were significantly more prevalent in IBS-constipation compared with IBS-diarrhea (OR = 2.3, 95% CI 1.2-4.2). In patients with IBS, proton pump inhibitor was not associated with SIBO (OR = 0.8, 95% CI 0.5-1.5, P = 0.55). DISCUSSION: This systematic review and meta-analysis suggests a link between IBS and SIBO. However, the overall quality of the evidence is low. This is mainly due to substantial "clinical heterogeneity" due to lack of uniform selection criteria for cases and controls and limited sensitivity and specificity of the available diagnostic tests.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shah A, Talley NJ, Jones M, et al. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Am J Gastroenterol. 2020. PMID: 31913194. doi:10.14309/ajg.0000000000000504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。